BioSpace News Archive

Drug Development

New Data Suggests Omicron More Contagious But Less Severe Than Delta

New real-world studies from Scotland and England shows that Omicron does not lead to as much hospitalization as Delta. This is consistent with the latest reports from South Africa that say Omicron causes milder disease.

December 23, 2021
·
2 min read
·
Mark Terry
Alcohol Dehydrogenase Market Is Expected to Drive Due to Increasing Adoption of Enzyme-Based Therapies Across Various End-Users for Treatment, Diagnosis, And Catalytic Applications – Reports and Data

The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and ML to enhance efficiency of medical products.

December 23, 2021
·
7 min read
Drug Development

FDA Authorizes Second Oral Antiviral for COVID-19

The FDA has greenlit Merck and Ridgeback’s molnupiravir under EUA to treat mild to moderate COVID-19 infections in adults at high risk of progression to severe disease.

December 23, 2021
·
3 min read
·
Alex Keown
Business

Genentech Plans to Eliminate 52 Jobs in January

When 2022 rolls around in a little more than a week, some Genentech employees will begin the new year in search of a new job.

December 23, 2021
·
2 min read
·
Alex Keown
FDA

New Drug Approved for Lowering Bad Cholesterol

The FDA has approved Novartis’ new drug for lowering bad cholesterol. Leqvio is the first and only siRNA treatment that can reduce low-density lipoprotein cholesterol.

December 23, 2021
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Novartis Drug Approved for Juvenile ERA and Psoriatic Arthritis

The latest approvals mark the first time a biologic has been approved for ERA. Cosentyx is also the only biologic approved in the United States for both ERA and PsA in pediatric patients.

December 23, 2021
·
2 min read
·
Alex Keown
Business

Janssen Cuts Ties with Theravance After IBD Program Flop

Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.

December 23, 2021
·
2 min read
·
Kate Goodwin
Drug Development

AstraZeneca’s Antibody Combo Still Effective Against Omicron

Studies found that AstraZeneca’s EVUSHELD was still effective against the Omicron variant. EVUSHELD is a long-acting antibody combination made up of tixagevimab and cilgavimab.

December 23, 2021
·
3 min read
·
Mark Terry
Drug Development

PhaseBio Pulls the Plug on Phase IIb Pulmonary Arterial Hypertension Trial

PhaseBio’s move to suspend its Phase IIb trial of pemziviptadil is due to the effect of COVID-19 on manufacturing, associated drug supply, and the rate of enrollment in the study.

December 23, 2021
·
2 min read
·
Sreetama Dutt
Wearable Injectors Market Size to Reach USD 15.66 Billion in 2028 Growing at a CAGR of 11.2%, says Emergen Research

According to Emergen Research, the global wearable injectors market size was USD 6.75 Billion in 2020 and is expected to reach USD 15.66 Billion in 2028 and register a revenue CAGR of 11.2% during the forecast period, 2021-2028.

December 23, 2021
·
6 min read